title: Developing treatments for pulmonary arterial hypertension.
abstract: Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes-prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for example, from studies with vasoactive intestinal polypeptide, statins and tergolide. Animal models are an unreliable predictor of efficacy in humans. The best model for the disease is the patient. This review discusses three major issues facing the evaluation of drugs in PAH patients-target validation, choosing the right dose, and early trial design.
authors: Imperial College London, Hammersmith Campus, London, UK.
authors: Martin R
authors: MR
authors: Wilkins
keywords: drug development; drug targets; early phase clinical trials; pulmonary hypertension
references: Respir Res. 2010 Jun 10;11:73
references: 20534176
references: Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1342-7
references: 17227868
references: Circulation. 2012 May 1;125(17):2128-37
references: 22451584
references: J Biopharm Stat. 2007;17(6):1033-50
references: 18027215
references: Circulation. 2010 Nov 16;122(20):2058-67
references: 21041689
references: Am J Hum Genet. 2000 Sep;67(3):737-44
references: 10903931
references: Circulation. 2010 Jan 5;121(1):52-62
references: 20026784
references: Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7
references: 20581169
references: Am J Respir Crit Care Med. 2012 Mar 15;185(6):670-9
references: 22246173
references: Respir Res. 2009 Sep 28;10:87
references: 19785764
references: Circulation. 2010 Jul 13;122(2):156-63
references: 20585011
references: J Am Coll Cardiol. 2011 Jul 12;58(3):300-9
references: 21737024
references: Nat Genet. 2000 Sep;26(1):81-4
references: 10973254
references: Nat Rev Drug Discov. 2011 May;10(5):328-9
references: 21532551
references: Am J Pathol. 2009 Feb;174(2):380-9
references: 19116361
references: Nat Rev Drug Discov. 2012 Jan 03;11(1):17-8
references: 22212671
references: Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1013-32
references: 19748998
references: Lancet. 2011 Feb 19;377(9766):658-66
references: 21315441